Control of the Erythroid Terminal Differentiation Decision

红细胞终末分化决策的控制

基本信息

  • 批准号:
    8344044
  • 负责人:
  • 金额:
    $ 36.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this project is to elucidate the factors and mechanisms that control the decision of early erythroid progenitors to undertake terminal differentiation. Much evidence suggests that a crucial aspect of differentiation decisions is a requirement for coordination with the cell proliferation program. However, our current knowledge about the connections between the cell proliferation and differentiation programs is very limited. Work from our lab and others has identified the Ets - family transcription factor PU.1 as a key regulator of the terminal differentiation decision in early erythroid progenitors. And yet, the factors that control PU.1 expression and activity in these early erythroid progenitors and the mechanisms that link the differentiation decision to the cell cycle are not known. Recently, we identified two types of factors that have a very strong potential for connecting PU.1 and the terminal differentiation decision to the cell cycle. One factor is CDK6, which we discovered inhibits erythroid differentiation, like PU.1. We also showed that: 1) CDK6 is the active G1 phase D-cyclin kinase in erythroid progenitors; 2) PU.1 controls transcription of the CDK6 gene; 3) CDK6 phosphorylates PU.1. The other factors are E2F2 and E2F4, transcriptions factors that play major roles in G1 to S phase cell cycle progression. We found that E2F2 and E2F4 occupy the promoter and upstream regulatory element (URE) of the PU.1 gene in erythroid progenitors. They also bind very close to PU.1 at many other PU.1 target genes in these cells. In Aims 1 and 2, we propose a series of experiments to determine how CDK6 and E2F2 and E2F4 influence PU.1 expression and activity and how they collaborate with PU.1 in the erythroid terminal differentiation decision. We also propose to investigate roles for CDK6 and E2F2 in stress erythropoiesis and in ex vivo self-renewal of erythroid precursors. Work from our lab and others showed that one of the principal mechanisms used by PU.1 to regulate the erythroid differentiation decision is repression of erythroid-specific gene expression Recently, we discovered that PU.1 forms a complex with the chromatin remodeling ATPase SNF2H and the maintenance DNA methyltransferase DNMT1; two enzymes that we hypothesize help PU.1 to repress erythroid gene expression. In Aim 3, we propose studies to elucidate the role of SNF2H and DNMT1 in PU.1-mediated repression of erythroid-specific genes and inhibition of erythroid terminal differentiation. The successful completion of the proposed studies will lead to new insights into the mechanisms connecting the proliferation and differentiation programs in hematopoietic cells and a much deeper understanding of how the hematopoietic system regulates red blood cell production, including during ontogeny and in stress conditions. The proposed work will also provide important information enabling the development of new approaches to managing defects in red blood cell production that occur in chronic and acute anemia. PUBLIC HEALTH RELEVANCE: The overall goal of this project is to understand the factors and mechanisms that regulate the decision of red blood cell precursors to undertake terminal differentiation into mature red blood cells. The proposed studies are expected to provide important new information about how the blood system normally produces the proper number of red blood cells and how it responds to the need to produce more red cells in stress conditions. Some of the proposed work will involve identification of factors that are required for expansion of red blood cell precursors ex vivo, an approach that could provide a source of red blood cells for transfusion therapy. The successful completion of this work will enable the development of new approaches to managing defects in red blood cell production that occur in chronic and acute anemia due to a variety of causes.
项目描述(由申请人提供):本项目的总体目标是阐明控制早期红系祖细胞进行终末分化决策的因素和机制。许多证据表明,差异化决策的一个关键方面

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARTHUR I SKOULTCHI其他文献

ARTHUR I SKOULTCHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARTHUR I SKOULTCHI', 18)}}的其他基金

Functions of Mammalian H1 Linker Histones in Gene Regulation and Chromatin Activity
哺乳动物 H1 连接组蛋白在基因调控和染色质活性中的功能
  • 批准号:
    10796397
  • 财政年份:
    2022
  • 资助金额:
    $ 36.32万
  • 项目类别:
Functions of Mammalian H1 Linker Histones in Gene Regulation and Chromatin Activity
哺乳动物 H1 连接组蛋白在基因调控和染色质活性中的功能
  • 批准号:
    10703445
  • 财政年份:
    2022
  • 资助金额:
    $ 36.32万
  • 项目类别:
Functions of Mammalian H1 Linker Histones in Gene Regulation and Chromatin Activity
哺乳动物 H1 连接组蛋白在基因调控和染色质活性中的功能
  • 批准号:
    10502018
  • 财政年份:
    2022
  • 资助金额:
    $ 36.32万
  • 项目类别:
Control of the Erythroid Terminal Differentiation Decision
红细胞终末分化决策的控制
  • 批准号:
    8667435
  • 财政年份:
    2012
  • 资助金额:
    $ 36.32万
  • 项目类别:
Control of the Erythroid Terminal Differentiation Decision
红细胞终末分化决策的控制
  • 批准号:
    8512590
  • 财政年份:
    2012
  • 资助金额:
    $ 36.32万
  • 项目类别:
Control of the Erythroid Terminal Differentiation Decision
红细胞终末分化决策的控制
  • 批准号:
    8874965
  • 财政年份:
    2012
  • 资助金额:
    $ 36.32万
  • 项目类别:
Drosophila Linker Histone H1 Functions in Chromosome Architecture and Activity
果蝇连接组蛋白 H1 在染色体结构和活性中的功能
  • 批准号:
    8213482
  • 财政年份:
    2011
  • 资助金额:
    $ 36.32万
  • 项目类别:
Drosophila Linker Histone H1 Functions in Chromosome Architecture and Activity
果蝇连接组蛋白 H1 在染色体结构和活性中的功能
  • 批准号:
    8403016
  • 财政年份:
    2011
  • 资助金额:
    $ 36.32万
  • 项目类别:
Drosophila Linker Histone H1 Functions in Chromosome Architecture and Activity
果蝇连接组蛋白 H1 在染色体结构和活性中的功能
  • 批准号:
    8043743
  • 财政年份:
    2011
  • 资助金额:
    $ 36.32万
  • 项目类别:
Drosophila Linker Histone H1 Functions in Chromosome Architecture and Activity
果蝇连接组蛋白 H1 在染色体结构和活性中的功能
  • 批准号:
    8601104
  • 财政年份:
    2011
  • 资助金额:
    $ 36.32万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 36.32万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了